Advanced or Metastatic Intrahepatic Cholangiocarcinoma (iCCA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Intrahepatic cholangiocarcinoma (iCCA)
is a rare, highly aggressive, and often fatal primary epithelial cancer arising
within the liver. iCCAs are diagnosed mainly at an advanced non-curable stage
and usually occur sporadically in patients without recognizable risk factors.
More than 90% of iCCAs are adenocarcinomas exhibiting biliary differentiation
biomarkers and can be subdivided by genomic and epigenomic profiling into
etiologically distinct subtypes. Unlike hepatocellular carcinoma (HCC), most
iCCAs develop in the non-cirrhotic liver, although it has been reported that
about 8–10% of all it occurs in patients with liver cirrhosis. Unlike
conventional HCCs, mass-forming iCCAs are typically characterized by a
prominent desmoplastic and hypovascularized tumor stroma, which often
represents the dominant histological feature of the tumor. Curative intent
surgical resection is the best option for achieving long-term survival
outcomes. However, only a fraction of iCCA patients are candidates for
corrective intent surgery. Moreover, the recurrence rates for iCCA after
surgery are very high, from 40 to 80%, with less than one-third of the patients
who undergo curative-intent surgery found to survive beyond five years after
resection.
·
The incidence of Intrahepatic
cholangiocarcinoma (iCCA) ranges from 0.5 to 1.04 per 100,000 population in the
USA.
Thelansis’s “Advanced or Metastatic
Intrahepatic Cholangiocarcinoma (iCCA) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Advanced
or Metastatic Intrahepatic Cholangiocarcinoma (iCCA) treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Advanced or Metastatic Intrahepatic Cholangiocarcinoma (iCCA) across 8 MM
market from the centre of Excellence/ Public/ Private hospitals participated in
the study. Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm, and Unmet needs.
Advanced or Metastatic Intrahepatic
Cholangiocarcinoma (iCCA) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment